This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:40 AM
Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine CI
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine CI
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing MT
Neurocrine Biosciences Says CEO Kevin Gorman Retiring MT
Neurocrine founder-CEO Gorman to retire in October RE
Neurocrine CEO set to retire RE
Neurocrine Biosciences, Inc. Announces Dr. Kyle Gano as Director, Effective October 11, 2024 CI
Neurocrine Biosciences Announces CEO Changes CI
UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating MT
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing MT
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis CI
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing MT
Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 CI
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 CI
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults CI
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 CI
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024 CI
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating MT
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell MT
Transcript : Neurocrine Biosciences, Inc., Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q1 Revenue $515.3M, vs. Street Est of $512M MT
Chart Neurocrine Biosciences, Inc.
More charts
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
135.4 USD
Average target price
160.5 USD
Spread / Average Target
+18.52%
Consensus
  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. News Neurocrine Biosciences, Inc.
  5. Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating